%0 Journal Article
%T Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review<br>
%A Hai-Hong Ran
%A Ran Zhang
%A Xue-Chun Lu
%A Bo Yang
%A Hui Fan
%A Hong-Li Zhu
%A <br>
%J 老年心脏病学杂志(英文版)
%D 2012
%I Science Press
%X Because it is safe and well tolerated, imatinib is a standard first-line therapy for chronic myeloid leukemia (CML). Although there have been sporadic reports of imatinib-induced cardiotoxicity, including left ventricle (LV) dysfunction and heart failure, the evidence for it is contradictory. Here, we reported a case of an 88-year-old male patient with CML developed decompensated heart failure following imatinib therapy. Four days after the initiation of imatinib, the patient developed orthopnea, edema and a pleural effusion accompanied by abdominal distension, nausea and vomiting. The chest X-ray film showed an enlarged cardiac profile. The echocardiogram demonstrated a decreased LV ejection fraction and enlarged left-side cardiac chambers. B-type natriuretic peptide concentrations were markedly increased. The patient recovered soon after the withdrawal of imatinib and introduction of comprehensive therapy for heart failure. Imatinib-induced cardiotoxicity in elderly patients is a potentially serious complication that merits further evaluation.
%K Heart failure
%K Chronic myeloid leukemia
%K Imatinib<br>
%U http://www.alljournals.cn/get_abstract_url.aspx?pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=AD36F34DDC3BA7B0&jid=4DC702B3A2386A4814E2FF9CFB799B27&aid=F1066E608B6765703AA036809F4F6EFD&yid=99E9153A83D4CB11&vid=9CF7A0430CBB2DFD&iid=E158A972A605785F&sid=34D9E20AD82A0D72&eid=3081401A9FAB9CE2&journal_id=1671-5411&journal_name=Journalofgeriatriccardiology:JGC&referenced_num=0&reference_num=0